Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
NVO Stock Up 3% as UBS Upgrades Company Rating From Neutral to Buy
Novo Nordisk stock gains 3% as analysts at UBS upgrade the company's rating from Neutral to Buy based on strong brand recognition of Ozempic and Wegovy.
Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs
Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using human data and artificial intelligence (AI).
Novo Nordisk Stock Jumps on Upgrade to 'Buy'
U.S.-listed shares of Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) are up 3.5% premarket, following a bull note from UBS.
Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pact
At least four analysts weighed in on the prospects for Europe's second-largest company, Novo Nordisk, after the Danish drugmaker reported disappointing results for its next-generation weight-loss drug.
Novo Nordisk Needs Answers to These 5 Key Questions
Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental obesity pill, and supply capacity for Ozempic and Wegovy.
Novo Nordisk (NVO) Suffers a Larger Drop Than the General Market: Key Insights
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $83.34, denoting a -1.99% change from the preceding trading day.
Trump's Danish Tariff Threat Means News Uncertainty for Ozempic Drugmaker Novo Nordisk
It's not at all clear what a tariff would mean for Novo, which manufactures its medicines in facilities all over the world, including in the U.S.
Seattle genomics startup Variant Bio signs deal with Novo Nordisk worth up to $50M
Variant Bio today announced a partnership with Novo Nordisk for disease research and development that could total $50 million for the biotech startup.
Novo Nordisk's Sponsorship Deals With UK Pharmacies Linked To Weight-Loss Drugs Raise Ethical Concerns
Novo Nordisk A/S NVO, the Danish pharmaceutical giant behind weight-loss drugs Wegovy and Saxenda, is facing scrutiny over its sponsorship deals with U.K. pharmacies.
Novo Nordisk upgraded to Market Perform from Underperform at Bernstein
Bernstein upgraded Novo Nordisk to Market Perform from Underperform.
Is Novo Nordisk an Undervalued Stock to Buy Now?
Novo Nordisk (NVO 0.15%) has sparked investor interest primarily because of its weight loss treatments.
